Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clene ( (CLNN) ) has issued an update.
On August 13, 2025, Clene Inc. announced amendments to its December 2024 senior secured convertible promissory notes, extending the maturity date to February 13, 2027, and postponing the commencement of monthly principal repayments to September 13, 2026. Additionally, the company entered into a new note purchase agreement with AE Capital Limited and others, issuing $1.5 million in senior secured convertible promissory notes. These financial maneuvers aim to provide Clene with a cash runway into the first quarter of 2026, supporting its ongoing clinical programs. Clene also reported its second quarter 2025 financial results, highlighting a net loss of $7.4 million and cash reserves of $7.3 million as of June 30, 2025. The company is advancing its CNM-Au8 programs for ALS and MS, with significant FDA meetings scheduled for the third quarter of 2025, aiming for a new drug application submission for ALS by the end of 2025.
The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
Spark’s Take on CLNN Stock
According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.
Clene’s overall stock score is primarily impacted by its financial instability, with significant losses and negative equity. However, positive corporate events, including regulatory progress and Nasdaq compliance, provide some optimism. Technical indicators offer mixed signals, while valuation remains challenging due to the lack of profitability.
To see Spark’s full report on CLNN stock, click here.
More about Clene
Clene Inc., along with its subsidiary Clene Nanomedicine, Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS). The company is based in Salt Lake City, Utah, with research and development and manufacturing operations in Maryland. Their investigational therapy, CNM-Au8, is designed to enhance central nervous system cell survival and function by targeting mitochondrial function and reducing oxidative stress.
Average Trading Volume: 90,521
Technical Sentiment Signal: Sell
Current Market Cap: $33.24M
Find detailed analytics on CLNN stock on TipRanks’ Stock Analysis page.